Skip to main content
Year archive

argenx SE — 2017 filings

All 95 regulatory filings released by argenx SE (1AE) in 2017, sourced directly from the official regulator.

95 Filings
2017 Period
2017 filings (95)
Filing Released Lang
argenx announces closing of U.S. public offering for gross proceeds of approximately $266 million
Share Issue/Capital Change
2017-12-19 English
424B4
Prospectus
2017-12-14 English
argenx raises approximately $231 million in gross proceeds in an upsized U.S. public offering
Share Issue/Capital Change
2017-12-14 English
Regulatory Filings 2017
Regulatory Filings
2017-12-14 English
F-1MEF
Regulatory Filings
2017-12-14 English
F-1/A
Regulatory Filings
2017-12-13 English
F-1/A
Regulatory Filings
2017-12-13 English
argenx announces launch of proposed public offering in the United States
Capital/Financing Update
2017-12-12 English
Regulatory Filings 2017
Regulatory Filings
2017-12-11 English
Regulatory Filings 2017
Regulatory Filings
2017-12-11 English
F-1
Regulatory Filings
2017-12-11 English
6-K
Foreign Filer Report
2017-12-11 English
argenx reports positive topline results from Phase 2 proof-of-concept trial of ARGX-113 (efgartigimod) in generalized myasthenia gravis
Earnings Release Q4 2017
2017-12-11 English
argenx to provide updates on Phase 1/2 clinical trials of ARGX-110 in Acute Myeloid Leukemia and Cutaneous T-Cell Lymphoma during American Society of Hematology Annual Meeting
Earnings Release Q4 2017
2017-12-11 English
Regulatory Filings 2017
Regulatory Filings
2017-11-14 English
argenx to Present at Upcoming Investor Conferences
Investor Presentation
2017-11-13 English
argenx announces results of extraordinary shareholders' meeting 2017
AGM Information
2017-11-07 English
6-K
Foreign Filer Report
2017-11-07 English
Regulatory Filings 2017
Regulatory Filings
2017-11-04 English
argenx to host KOL breakfast symposium on pemphigus vulgaris on November 10, 2017
Regulatory Filings
2017-11-02 English
6-K
Foreign Filer Report
2017-10-30 English
argenx launches Phase I trial with subcutaneous formulation of ARGX-113
Earnings Release Q4 2017
2017-10-30 English
6-K
Foreign Filer Report
2017-10-26 English
6-K
Foreign Filer Report
2017-09-26 English
argenx launches Phase II proof-of-concept clinical trial of ARGX-113 for the treatment of pemphigus vulgaris
Regulatory Filings
2017-09-26 English
6-K
Foreign Filer Report
2017-09-25 English
argenx announces orphan drug designation for ARGX-113 for the treatment of myasthenia gravis
Regulatory Filings
2017-09-25 English
6-K
Foreign Filer Report
2017-09-22 English
Invitation to the extraordinary shareholders' meeting
AGM Information
2017-09-22 English
6-K
Foreign Filer Report
2017-09-20 English
argenx reaches 50% enrollment in Phase 2 clinical trial of ARGX-113 in immune thrombocytopenia
Regulatory Filings
2017-09-20 English
Interim / Quarterly Report 2017
Interim / Quarterly Report H1 2017
2017-09-05 English
6-K
Foreign Filer Report
2017-08-24 English
argenx reports second quarter business update and half-year 2017 financial results
Interim / Quarterly Report H1 2017
2017-08-24 English
6-K
Foreign Filer Report
2017-08-23 English
argenx to host conference call & webcast to report second quarter business update and half year 2017 financial results on August 24, 2017
Earnings Release H1 2017
2017-08-17 English
6-K
Foreign Filer Report
2017-07-07 English
argenx receives second preclinical milestone payment in collaboration with LEO Pharma
Regulatory Filings
2017-06-20 English
6-K
Foreign Filer Report
2017-06-20 English
6-K
Foreign Filer Report
2017-06-14 English
argenx presents update on Phase I data from ARGX-110 expansion study in patients with cutaneous T-cell lymphomas at the International Conference of Malignant Lymphoma (ICML)
Regulatory Filings
2017-06-14 English
argenx to Present at JMP Securities Life Sciences Conference
Regulatory Filings
2017-06-13 English
argenx announces closing of NASDAQ IPO
Share Issue/Capital Change
2017-05-24 English
6-K
Foreign Filer Report
2017-05-23 English
AUTO-GENERATED PAPER DOCUMENT
Regulatory Filings
2017-05-22 English
argenx announces full exercise of underwriters’ option to purchase additional ADSs
Share Issue/Capital Change
2017-05-19 English
424B4
Prospectus
2017-05-19 English
Regulatory Filings 2017
Regulatory Filings
2017-05-18 English
argenx raises approximately $100 million gross proceeds with NASDAQ IPO
Share Issue/Capital Change
2017-05-18 English
Regulatory Filings 2017
Regulatory Filings
2017-05-18 English
F-1MEF
Regulatory Filings
2017-05-18 English
Regulatory Filings 2017
Regulatory Filings
2017-05-17 English
AUTO-GENERATED PAPER DOCUMENT
Regulatory Filings
2017-05-17 English
Regulatory Filings 2017
Regulatory Filings
2017-05-17 English
F-1/A
Regulatory Filings
2017-05-17 English
8-A12B
Regulatory Filings
2017-05-16 English
Regulatory Filings 2017
Regulatory Filings
2017-05-16 English
Regulatory Filings 2017
Regulatory Filings
2017-05-16 English
FWP
Regulatory Filings
2017-05-16 English
Regulatory Filings 2017
Regulatory Filings
2017-05-16 English
F-1/A
Regulatory Filings
2017-05-16 English
argenx announces size of initial public offering in the United States increased to 5 million ADSs
Share Issue/Capital Change
2017-05-16 English
Regulatory Filings 2017
Regulatory Filings
2017-05-15 English
argenx announces launch of proposed initial public offering in the United States
Capital/Financing Update
2017-05-08 English
Regulatory Filings 2017
Regulatory Filings
2017-05-08 English
F-1/A
Regulatory Filings
2017-05-08 English
Regulatory Filings 2017
Regulatory Filings
2017-05-05 English
argenx reaches 50% enrollment in Phase 2 clinical trial of ARGX-113 in myasthenia gravis
Regulatory Filings
2017-05-04 English
Regulatory Filings 2017
Regulatory Filings
2017-05-04 English
F-1/A
Regulatory Filings
2017-05-04 English
Regulatory Filings 2017
Regulatory Filings
2017-05-03 English
argenx reports first quarter 2017 financial results and provides business update
Earnings Release Q1 2017
2017-05-03 English
argenx announces results of Annual General Meeting 2017
AGM Information
2017-04-26 English
argenx files registration statement for a proposed public offering in the United States
Capital/Financing Update
2017-04-24 English
Regulatory Filings 2017
Regulatory Filings
2017-04-21 English
F-1
Regulatory Filings
2017-04-21 English
Regulatory Filings 2017
Regulatory Filings
2017-04-19 English
argenx receives first preclinical milestone payment in AbbVie collaboration
Regulatory Filings
2017-04-14 English
argenx launches Phase II study of ARGX-110 as a monotherapy in relapsed/refractory CTCL patients
Earnings Release Q2 2017
2017-04-12 English
Regulatory Filings 2017
Regulatory Filings
2017-04-05 English
Regulatory Filings 2017
Regulatory Filings
2017-04-05 English
argenx announces first patient dosed in Phase II proof-of-concept study of ARGX-113 for the treatment of primary immune thrombocytopenia
Regulatory Filings
2017-03-31 English
Regulatory Filings 2017
Regulatory Filings
2017-03-29 English
argenx announces collaboration with Broteio Pharma to develop therapeutic antibody for severe autoimmune diseases
M&A Activity
2017-03-21 English
Annual Report 2016
Annual Report FY 2016
2017-03-15 English
argenx reports fourth quarter business update and full year 2016 financial results
Earnings Release FY 2016
2017-03-15 English
argenx announces Annual General Meeting of Shareholders 26 April 2017
AGM Information
2017-03-15 English
argenx to Host Conference Call & Webcast to Report Fourth Quarter Business Update and Full Year 2016 Financial Results on March 15, 2017
Report Publication Announcement
2017-03-09 English
argenx announces that Staten Biotech exercised its option to develop therapeutic SIMPLE AntibodyTM for dyslipidemia
Capital/Financing Update
2017-03-06 English
argenx announces intention to conduct a registered public offering in the United States
Capital/Financing Update
2017-03-02 English
Regulatory Filings 2017
Regulatory Filings
2017-03-01 English
argenx to Present at Cowen & Co 37th Annual Health Care conference
Report Publication Announcement
2017-02-28 English
argenx announces extension of therapeutic antibody alliance with Shire
Capital/Financing Update
2017-02-27 English
argenx to Present at Leerink Partners 6th Annual Global Healthcare Conference
Investor Presentation
2017-02-09 English
argenx launches Phase II proof-of-concept study of ARGX-113 for the treatment of myasthenia gravis
Regulatory Filings
2017-01-09 English